Valuation: Xencor, Inc.

Market Cap 1.74B 1.5B 1.41B 1.28B 2.41B 166B 2.44B 16.5B 6.46B 83.13B 6.52B 6.37B 277B P/E 2026 *
-7.68x
P/E 2027 * -7.35x
Enterprise Value 1.3B 1.12B 1.06B 962M 1.81B 124B 1.83B 12.38B 4.85B 62.39B 4.89B 4.78B 208B EV / Sales 2026 *
9.05x
EV / Sales 2027 * 13.8x
Free-Float
98.78%
Yield 2026 *
-
Yield 2027 * -
1 day-0.94%
1 week+11.10%
Current month+14.40%
1 month+54.65%
3 months+106.06%
6 months+99.48%
Current year+51.01%
1 week 21.38
Extreme 21.38
23.47
1 month 17.62
Extreme 17.62
23.47
Current year 10.38
Extreme 10.375
23.47
1 year 7.13
Extreme 7.13
23.47
3 years 6.92
Extreme 6.92
27.24
5 years 6.92
Extreme 6.92
43.61
10 years 6.92
Extreme 6.92
58.34
Manager TitleAgeSince
Chief Executive Officer 55 2005-01-31
Director of Finance/CFO 48 2024-04-08
Chief Tech/Sci/R&D Officer 61 2006-09-30
Director TitleAgeSince
Director/Board Member 55 1997-07-31
Director/Board Member 58 2014-07-24
Director/Board Member 72 2015-03-17
Date Insider Type Main position Quantity % Market Cap.
6/16/26 Free

Director

30,906 0.0417%
1/23/26 Fiscal year

Chief Technology Officer

10,644 0.0149%
12/19/25 Fiscal year

Chief Technology Officer

232,723 0.3259%
Change 5-day change 1-year change 3-year change Capi.($)
-0.94%+11.10%+201.04%+2.44% 1.74B
+4.80%+7.80%+70.64%+114.21% 70.07B
+17.12%+12.05%+54.42%+86.20% 52.87B
+3.70%-2.12%+0.41%+469.55% 27.02B
+2.26%+0.65%+49.19%+10.30% 23.61B
-1.60%-2.21%-19.31%-15.15% 23.38B
-6.00%+13.71%+244.39%+443.26% 19.43B
+3.80%+5.25%+40.50%-16.41% 18.75B
+0.38%-3.15%+20.39%+589.77% 15.85B
+2.11%-3.24%+36.57%+145.40% 12.7B
Average +2.56%-0.66%+69.82%+182.96% 26.54B
Weighted average by Cap. +5.06%-1.06%+57.24%+168.20%

Financials

2026 *2027 *
Net sales 144M 124M 117M 106M 200M 13.76B 203M 1.37B 536M 6.89B 540M 529M 22.94B 126M 108M 102M 92.75M 174M 12.01B 177M 1.19B 467M 6.02B 472M 461M 20.03B
Net income -238M -206M -193M -176M -331M -22.79B -336M -2.27B -887M -11.42B -895M -876M -38.01B -280M -241M -227M -206M -388M -26.72B -393M -2.66B -1.04B -13.39B -1.05B -1.03B -44.56B
Net Debt -433M -374M -351M -320M -601M -41.39B -609M -4.12B -1.61B -20.74B -1.63B -1.59B -69.03B -
Logo Xencor, Inc.
Xencor, Inc. is a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases. It has more than 20 candidates engineered with its XmAb technology that are in clinical development, and multiple XmAb medicines are marketed by partners. Its XmAb engineering technology enables small changes to a protein structure that result in new mechanisms of therapeutic action. Its wholly-owned development candidates include XmAb942, XmAb819, XmAb808, and XmAb541. Candidates co-developed with partners include Plamotamab. Its clinical-stage drug candidates advanced by partners include Xaluritamig (AMG 509), ASP2138, JNJ-9401, JNJ-1493, Xpro1595, Obexelimab, and Novartis XmAb, an undisclosed antibody candidate. Its cytokine drug candidates in clinical development consist of efbalropendekin alfa (XmAb306/RG6323). Its Vudalimab is a bispecific antibody that targets PD-1 and CTLA-4.
Employees
260
Date Price Change Volume
26-08-17 US$23.12 -0.94% 920,251
26-08-14 US$23.34 +1.52% 443,070
26-08-13 US$22.99 -0.82% 975,295
26-08-12 US$23.18 +4.89% 1,967,662
26-08-11 US$22.10 +2.41% 1,109,981
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
14
Last Close Price
23.34USD
Average target price
29.00USD
Spread / Average Target
+24.25%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. XNCR Stock